Navigation Links
Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/23/2007

BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Convention Center, San Francisco, Calif.

In a poster session, Tapestry investigators will be discussing data from preclinical studies of TPI 287, the company's proprietary next-generation taxane for the treatment of multiple cancer indications, on Tuesday, October 23, 2007 from 12:30 - 2:30 PM Pacific Time in the Drug Resistance Session A:

Poster #192: "TPI 287, A Next Generation Taxane Derivative, Functionally

Modulates MDR1 P-glycoprotein Drug Transport Pump and is Active in

Resistant Tumor Cells"

The poster outlines a number of different assays confirming Tapestry's observation that its lead drug candidate TPI 287 is less sensitive in a variety of cancer cell lines to MDR1 mediated efflux than other approved taxanes. MDR1 mediated drug efflux may be a primary cause of resistance to chemotherapy with taxanes.

Additionally, TPI 287 is retained at higher levels in MDR1 expressing cell lines than either paclitaxel or IDN 5109, another taxane in development purported to be active in MDR1 expressing tumors. In addition, TPI 287 has demonstrated tumor growth inhibition when delivered orally in subcutaneous mouse xenograft models of both pancreatic cancer and glioblastoma multiforme (GBM). Tapestry has Phase 2 studies underway for TPI 287 in pancreatic and prostate cancer. The Company plans to evaluate TPI 287 in a Phase 2 study in GBM. A copy of the poster is available on Tapestry's website at '/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013  It may seem like an odd pairing: ... cancer. But these were two of the most talked about ... Annual Meeting & Expo that just convened in ... focus by some of the top internal medicine experts in ... new research that can not only save lives, but help ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... focused on the development and commercialization of novel bile ... the pricing of an underwritten public offering of 1,730,000 ... price of $33.01 per share.  In addition, Intercept has ... to an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... Inc. (NYSE: ACT ) today announced that Actavis ... Exchange Commission (SEC) a registration statement on Form S-4 in ... plc (NASDAQ: WCRX ), which included a joint ... "Form S-4"). As previously announced on May 20, ... a definitive agreement pursuant to which Actavis will acquire ...
Breaking Medicine Technology:"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... (Nasdaq: ARAY ), the premier radiation ... Especialidad in Monterrey, Mexico has starting treating patients with ... is the first center in Mexico now offering patients ... anywhere in the body. The CyberKnife System ...
... Jan. 17, 2012  Ventana Medical Systems, Inc. (Ventana), ... that it has entered into a strategic collaboration ... a molecular companion diagnostic test intended to identify ... Bayer antibody-drug conjugate (ADC). Ventana,s diagnostic immunohistochemistry platform ...
Cached Medicine Technology:First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 3First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 4Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy 2Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy 3
(Date:6/19/2013)... The former internist for the St. Louis ... serves as director of prevention and wellness at St. ... personal encounter with a metabolic syndrome diagnosis and a ... , that he credits with sparking the paradigm-shift that ... practice. , “The average medical student gets 30 minutes ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... The US Food and Drug Administration (FDA) announced ... breast implant, Mentor Worldwide’s MemoryShape™. , The FDA approved Sientra/Silimed ... FDA announced the approval of the MemoryShape™ implant on June ... in women 22 years old or older and in ... FDA’s approval comes after six years of data from 955 ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
... The study team involving researchers from the U.S. Army ... Microbiology Laboratory// at the Public Health Agency of Canada ... protect monkeys by in preventing hemorrhagic fever in monkeys ... Could also provide the first known treatment for the ...
... psychologist and Professor Saul Shiffman has revealed that people who ... likely to bounce back to a complete relapse, if they ... in Smoking Cessation: Illustration in a Nicotine Patch Trial in ... in the Journal of Consulting and Clinical Psychology. ...
... not offer protection against cardiovascular disease, despite the lofty ... trial has shown.// The findings of the trial have ... American Journal of Epidemiology. ,Selenium now joins the ... particular, that were praised for its role in preventing ...
... go a long way in increasing the life expectancy of ... smoking,// exercising more and eating better could increase your life ... ,Researchers led by Professor Kay-Tee Khaw studied 25,663 men and ... in Norfolk and found small lifestyle changes could have a ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... health officials are demanding the government to take radical ... Lynne Kosky announced// a ban on high-sugar soft drinks ... Haikerwal said that this was not going to change ... measures. ,He said that the present generation ...
Cached Medicine News:Health News:New Vaccine To Combat The Deadly Marburg Virus 2
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
The Small External Fixator has straight or angled frames, independent pin placement, and combines easily with Large and Medium External Fixator frames....
... Fixation System for distal radius fractures allows ... length and rotation. The unique wrist lock ... into extension without losing fracture reduction. Post-op ... the surgeons office. Priced competitively and sold ...
Medicine Products: